AmplifyBio and Xcell Biosciences have announced a strategic collaboration to advance the manufacturing process for engineered T-cell receptor (TCR) therapies. The alliance will focus on optimising and enhancing the production process of TCR therapies targeting solid tumours. The gold standard of business intelligence.
The companies will utilise the AVATAR Foundry platform of Xcellbio and work together through the process development, preclinical assessment and first-in-human clinical trials. Xcell previously developed the AVATAR incubator system, which is instrumental in cell and gene therapy research and development. A cGMP cell therapy manufacturing system, AVATAR Foundry is designed to enhance the potency of cell and gene therapies.
AmplifyBio scientists will collaborate with the Xcell team to create new cell therapy manufacturing methods utilising the AVATAR Foundry platform. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form The joint efforts will concentrate on detecting critical factors for the successful production of TCR therapies.
They include establishing a product characterisation matrix, understanding the correlation to the met.